SDH-Engine

Drug Repurposing Engine

DashboardDrug CandidatesAI HypothesesResearch FeedClinical TrialsAbout / Methods

Targeting SDH-deficient GIST, paraganglioma, pheochromocytoma, RCC

Drug Candidates

4 candidates mapped to SDH-deficient disease pathways

All (15)established (4)clinical trial (2)preclinical (6)theoretical (3)
Olaparib

Lynparza

theoretical

PARP inhibitor

Oxidative Stress Ros
Evidence Score
45
FDA Approved
Metformin

Glucophage

preclinical

Biguanide / Complex I inhibitor / AMPK activator

Mtor Pi3k AktOxidative Stress Ros
Evidence Score
40
FDA Approved
Ascorbic Acid (High-dose IV)
preclinical

TET enzyme cofactor / α-KG-dependent dioxygenase activator

Epigenetic DysregulationOxidative Stress Ros
Evidence Score
38
Dichloroacetate (DCA)
preclinical

Pyruvate dehydrogenase kinase inhibitor

Hif PseudohypoxiaOxidative Stress Ros
Evidence Score
35